Mendel, a San Jose, CA-based leading clinical artificial intelligence and natural language processing platform, announced that it raised $40 million in Series B funding.
The round was led by Oak HC/FT, with participation from existing investor DCM, who led Mendel's Series A funding round in June 2021.
This funding comes amidst surging customer demand for Mendel's AI infrastructure. The fresh capital will enable the company to expand its team of AI and engineering teams and scale the commercial organization.
It will also help accelerate the release of Mendel's new, breakthrough product, Resolve, which consolidates clinical information to create a coherent longitudinal view of the patient journey.
Round: Series B
Funding Month: April 2022
Lead Investors: Oak HC/FT
Additional Investors: DCM
Company Website: https://www.mendel.ai/
Software Category: Clinical Artificial Intelligence and Natural Language Processing platform
About the Company: Mendel is a machine that can read and understand medicine. Mendel’s mission is to use its novel AI aided by clinical experts to streamline global oncology research by organizing real-world data and automating clinical trials. Mendel builds software to solve problems at each stage of the clinical trial process, from feasibility to post-trial pharmacovigilance. Mendel Health is a for-profit corporation headquartered in San Jose, California that uses novel AI technology to absorb clinical data in medical literature as well as patient health records, to unlock a wide range of Real-World Data applications.